ArticleJapanese journal of ophthalmology2026
Oral methotrexate as a steroid-sparing therapy after high-dose intravenous corticosteroid pulse therapy for refractory Vogt-Koyanagi-Harada disease.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn Japan, high-dose corticosteroids serve as the first-line treatment for Vogt-Koyanagi-Harada disease (VKHD), whereas cyclosporine (CysA) and adalimumab are reserved for recurrent cases. However, some patients require prolonged corticosteroid therapy despite these immunosuppressants. Our institution generally utilizes CysA as the first-line steroid-sparing immunosuppressive agent and low-dose methotrexate (MTX; 6-8 mg/week) as a second-line or alternative therapy. We evaluated recurrence rates and treatment-related adverse effects, focusing on MTX. STUDY
designRetrospective observational study.
methodsWe reviewed 64 patients with first-onset VKHD treated with systemic corticosteroids (high-dose intravenous pulse therapy followed by oral prednisolone [PSL]) between April 2017 and April 2024. Recurrence was defined as the reappearance of intraocular inflammation after initial control. Clinical data regarding recurrence patterns and subsequent treatments, including MTX and CysA, were analyzed.
resultsThe cohort comprised 28 men and 36 women (mean age, 52.3 ± 15.4 years). Twenty-two of 64 patients (34%) experienced recurrence. Among these, 15 patients received CysA; 8 required switching to MTX because of insufficient disease control, difficulty tapering corticosteroids, or CysA-related adverse effects. After initiating MTX, six of eight patients discontinued PSL after a median of 17.5 months and remained recurrence-free during a median of 10 months. In contrast, among seven patients treated with CysA alone, five discontinued PSL after 34 months and remained recurrence-free for 24 months. No severe MTX-related adverse effects were observed.
conclusionLow-dose MTX was well tolerated and enabled discontinuation of corticosteroids in patients with recurrent VKHD, supporting its utility as a feasible steroid-sparing therapy.
Indexed as
Identifiers
42828612What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.